Summary & Overview
HCPCS Level II C9160: Injection, daxibotulinumtoxina-lanm, 1 unit
Headline: HCPCS Level II code C9160: Unit-based billing for daxibotulinumtoxina-lanm injections
Lead: HCPCS Level II code C9160 denotes billing for a single unit of daxibotulinumtoxina-lanm, a botulinum toxin product used for targeted neuromuscular blockade. The code standardizes reporting for unit-based administration of this agent across outpatient and office-based settings.
Why it matters: Accurate use of HCPCS Level II code C9160 matters nationally for consistent claims submission, utilization tracking, and payment processing for botulinum toxin therapies used in therapeutic indications. Unit-based coding affects clinical documentation, dose accounting, and cost reporting across payers.
Payers in focus: This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication provides benchmarks and national context for billing and utilization of C9160, summarizes payer coverage patterns and common billing modifiers, and outlines the clinical service context and typical sites of service where the code is used. It also flags areas where input data is not available and indicates where stakeholders may need additional documentation to support claims.
Additional context: The content emphasizes unit-level billing implications and clinical settings for daxibotulinumtoxina-lanm administration without issuing clinical recommendations.
Billing Code Overview
HCPCS Level II code C9160 describes an injection of daxibotulinumtoxina-lanm, 1 unit. This code represents a billed unit for administration of a botulinum toxin product formulated as daxibotulinumtoxina-lanm.
Service Type: Therapeutic neuromuscular blockade / neurotoxin injection
Typical Site of Service: Outpatient clinic, physician office, or ambulatory infusion/ procedure suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 46-year-old patient with chronic cervical dystonia presents to a neurology clinic for therapeutic botulinum toxin injections. The clinician selects C9160 (Injection, daxibotulinumtoxina-lanm, 1 unit) to document units used. The clinical workflow includes: initial evaluation with review of symptoms and prior response to botulinum toxins; localization of hyperactive muscles by physical exam (and electromyography if needed); informed consent discussion about risks and benefits; preparation of daxibotulinumtoxin product and drawing up the appropriate number of units; injection into targeted neck muscles using anatomical landmarks and, when indicated, EMG or ultrasound guidance; post‑procedure observation for immediate adverse reactions for 15–30 minutes; and scheduling follow-up to assess efficacy and plan repeat injections at appropriate intervals. Documentation includes indication, muscles injected, units per site, total units (via C9160 units), guidance technique used, informed consent, and any immediate adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the work required is substantially greater than typically required. |